Table 16.
Expression (%) of costimulatory and LNH molecules on mDC1s in the blood of women with LLABCs undergoing NAC. Baseline (B) levels in LLABCs versus completion of chemotherapy (CC) levels in different responders.
| Study group comparisons | CD40 | CD80 | CD83 | CD86 | CD197 | |
|---|---|---|---|---|---|---|
| Good pathological responders (GPR: n = 9) | B (%) | 40.60 ± 10.00 | 2.02 ± 1.30 | 4.45 ± 0.75 | 40.97 ± 14.00 | 31.29 ± 8.00 |
| CC (%) | 43.13 ± 10.00 | 3.83 ± 2.00 | 3.71 ± 1.70 | 28.66 ± 7.00 | 48.34 ± 14.00 | |
| B versus CC (p value) |
NS | NS | NS | NS | NS | |
| CC versus HFDs (p value) |
NS | NS | NS | NS | NS | |
|
| ||||||
| Poor pathological responders (PPRs: n = 7) | B (%) | 26.80 ± 10.00 | 1.48 ± 0.50 | 2.98 ± 2.00 | 21.37 ± 10.00 | 22.73 ± 6.00 |
| CC (%) | 16.80 ± 8.00 | 2.29 ± 1.20 | 4.47 ± 1.80 | 6.81 ± 6.00 | 13.83 ± 5.00 | |
| B versus CC (p value) |
NS | NS | NS | NS | NS | |
| CC versus HFDs (p value) |
0.001∗ | NS | NS | 0.001∗ | NS | |
|
| ||||||
| Post-NAC GPR versus PPR | GPR CC versus PPR CC (p value) |
0.005∗ | NS | NS | 0.004∗ | 0.003∗ |
LNH: lymph node homing; LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; GPRs: complete or >90% reduction of tumour cell mass; PPRs: no or ≤90% reduction of tumour cell mass; HFDs: healthy female donors; NS: nonsignificant; ∗statistically significant.